A Chinese Startup Just Dropped Eczema Data That Should Worry Dupixent

Of course, zemprocitinib isn't the only oral JAK inhibitor eyeing this market. AbbVie's upadacitinib (Rinvoq) and Pfizer's abrocitinib already have approvals. So what makes this one worth watching?

The Safety Question That Haunts Every JAK Inhibitor

If you follow biotech at all, you know that JAK inhibitors carry baggage. The FDA slapped class-wide boxed warnings on all oral JAK inhibitors after a long-term study of tofacitinib (Xeljanz) in rheumatoid arthritis patients showed increased risks of heart problems, blood clots, cancer, and death. It's the scariest label a drug can carry, and it was applied broadly to the entire class, even to drugs that weren't in the original study.

That's a bit like banning all SUVs from a highway because one model had faulty brakes. Dermatologists have pushed back, noting that eczema patients are generally younger and healthier than rheumatoid arthritis patients, with fundamentally different risk profiles. Still, the black box sits there like a flashing neon sign, scaring off some prescribers and patients.

Lynk is positioning zemprocitinib as a "next-generation" selective JAK1 inhibitor with a better safety profile. In the Phase III data, most side effects were mild to moderate (Grade 1 or 2). Rates of serious adverse events and treatment discontinuations were low, comparable to placebo. No new safety signals popped up, and lab values for blood counts and liver enzymes stayed clean.

That's encouraging, but it comes with a massive asterisk: these are 16-week results. The cardiovascular concerns that triggered those boxed warnings emerged from long-term data. Whether zemprocitinib can maintain this clean profile over years of use is a question only time (and larger studies) can answer.

Who Is Lynk, Anyway?

Lynk Pharmaceuticals was founded in 2018 by a team of veterans from Pfizer, Merck, and Johnson & Johnson. They've raised over $100 million across multiple funding rounds, backed by Lilly Asia Ventures, Legend Capital, Decheng Capital, and others.

The company isn't a one-trick pony, either. In January 2026, zemprocitinib posted strong Phase III results in rheumatoid arthritis (79.1% of patients hit the ACR20 response target versus 39.7% on placebo). And in December 2025, Lynk signed an exclusive licensing deal with Formation Bio for a different asset, a TYK2 inhibitor called LNK01006, worth up to $605 million in milestones.

That's a lot of momentum for a company most people outside China haven't been tracking.

The Dupixent Dynasty Isn't Over (Yet)

Let's be clear: nobody is dethroning Dupixent tomorrow. It has years of real-world safety data, approvals across multiple age groups (down to infants over 6 months), and the kind of brand recognition that makes dermatologists reach for it first. Biologics as a class held 43% of the eczema treatment market in 2025.

But the market is shifting. JAK inhibitors and related oral therapies are growing at roughly 11% per year, outpacing the broader market. Patients want options, and many prefer pills over injections. If next-generation JAK inhibitors can chip away at the safety concerns hanging over the class, Dupixent's dominance could erode faster than Sanofi would like.

What Comes Next

Lynk says full data analysis is ongoing, with publication to follow. No regulatory filing timeline has been announced yet, though the company's CEO, Dr. Zhao-Kui Wan, called the results proof of zemprocitinib's "positioning as a core asset" with a "potentially differentiated profile in the competitive JAK landscape."

The road from Phase III topline data to regulatory approval is long, especially for a China-based company seeking global reach. But the clinical data is real, the market is enormous, and the unmet need is genuine. Millions of eczema patients are still looking for something better.

Zemprocitinib just raised its hand.